




The XEOMIN Difference

XEOMIN Patients Did Not Develop Clinical Resistance Due to Neutralizing Antibodies (NAb)

Incidence of NAb was negligible

Of 2400 patients treated with XEOMIN in clinical trials, no patients demonstrated clinical resistance or secondary treatment failure due to NAb.



WARNINGS AND PRECAUTIONS

The potency Units of XEOMIN are specific to the preparation and assay method used and are not interchangeable with other preparations of botulinum toxin products. Therefore, Units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products.